Related Experiment Video
Updated: May 29, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Use of cefoperazone/sulbactam in neonates
Fahri Ovali1, Tugba Gursoy, Ilkay Sari
1Neonatal Intensive Care Unit, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.
Background:
Neonates are at high risk for nosocomial infections due to multidrug-resistant pathogens. The use of β-lactamase inhibitors in combination with β-lactam antibiotics broadens the antimicrobial spectrum. Cefoperazone/sulbactam is used in children but there are limited data on its usage in neonates. The purpose of the present study was therefore to evaluate the use of cefoperazone/sulbactam in the treatment of neonatal infections caused by multidrug-resistant pathogens.
Methods:
The records of neonates who were hospitalized and who received cefoperazone/sulbactam were reviewed.
Results:
There were 90 infants who received cefoperazone/sulbactam. A pathogen could be isolated in 41 (45.6%) of the infants. In total, 17.1% of isolated pathogens were resistant to cefoperazone/sulbactam. Side-effects were seen in four of the infants. Two infants had cholestasis, one infant had neutropenia and one had superinfection with candida.
Conclusion:
Cefoperazone/sulbactam can be used in the treatment of nosocomial infections caused by multidrug-resistant pathogens in neonates.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Urine Studies II: Urine Culture and Sensitivity Test
Acute Pyelonephritis II: Diagnostic Studies and Management
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

